In ER+ breast cancer cells harboring PIK3CA and PTEN mutations, treatment with a PI3K/mTOR inhibitor resulted in increased RTK-mediated signaling and upregulation of EGFR/ERK/p-BadS112. This evidence concerns the gene MTOR and breast cancer.